Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - metformin hydrochloride -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - metformin hydrochloride -

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - metformin hydrochloride - modified-release tablet - 750mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - metformin hydrochloride - modified-release tablet - 1gram

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 500 mg - 500 mg

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 850 mg - 850 mg

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 1 g - 1 g

Iisrael - inglise - Ministry of Health

merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 1000 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Iisrael - inglise - Ministry of Health

merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 500 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Iisrael - inglise - Ministry of Health

merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 750 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.